Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Free Cash Flow (2024 - 2025)

Kairos Pharma (KAPA) has disclosed Free Cash Flow for 2 consecutive years, with -$805000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Free Cash Flow fell 379.17% year-over-year to -$805000.0, compared with a TTM value of -$5.3 million through Jun 2025, changed N/A, and an annual FY2024 reading of -$4.0 million, down 4982.72% over the prior year.
  • Free Cash Flow was -$805000.0 for Q2 2025 at Kairos Pharma, down from -$714000.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $36000.0 in Q1 2024 and bottomed at -$2.0 million in Q3 2024.